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Abstract 
We report here our investigation of the role of cyclic AMP (cAMP) in amylin signal transduction i isolated strips of soleus muscle. 
Rat amylin, at 100 nM, increased cAMP levels, from 0.431 ___ 0.047 to a peak of 1.24 _ 0.01 pmol cAMP/mg wet wt. after 5 min, in the 
absence of added phosphodiesterase inhibitor. The ECso of the response was 0.48 nM (___ 0.12 log units) in the absence of insulin and 0.3 
nM (± 0.18 log units) in the presence of 7.1 nM insulin. The response seen with a maximally effective concentration f amylin (10 nM) 
was similar to that seen with a maximally effective concentration f epinephrine (1 /.tM) under the same conditions. Consistent with the 
observed rise in cAMP there yeas an increase in glycogen phosphorylase a (ECs0 2.2 nM + 0.25 log units), decreased glycogen content 
(ECso 9.9 nM + 0.22 log units) and enhanced production of lactate (ECs0 1.5 nM + 0.33 log units). These data support he concept hat 
amylin promotes glycogenoly:~is in keletal muscle and enhances production of lactate through glycolysis as a result of activation of Gs 
coupled receptors, timulation of adenylate cyclase, elevation of cAMP levels and activation of glycogen phosphorylase. 
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1. Introduction 
Amylin, a 37-amino acid peptide (sometimes referred to 
as ' lAPP' or islet amyloid polypeptide) originally purified, 
sequenced and characterized from islet amyloid deposits 
found in patients with non-insulin dependent diabetes mel- 
iitus (NIDDM) [1-3], is cosecreted with insulin by pancre- 
atic /3-cells in response to nutrient secretagogues [4]. 
Plasma levels of amylin have been reported to be elevated 
in insulin-resistant s ates in man and animals [5-7] and 
reduced or unmeasurable in juvenile onset diabetes [8]. In 
isolated soleus muscle, amylin dose-dependently inhibits 
insulin-stimulated glucose incorporation i to glycogen [9- 
11]. Amylin has also been reported to inhibit glycogen 
synthase [12] and stimulate glycogen phosphorylase [12,13] 
resulting in decreased glycogen content [12,14]. These 
actions in muscle are proposed to underly amylin's ability 
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to induce hyperlactemia and hyperglycemia n intact rats 
[15,16]. 
Amylin which is approx. 50% homologous with calci- 
tonin gene-related peptide (CGRP), has been reported to 
have weak CGRP-like effects in stimulating adenylate 
cyclase activity in cultured skeletal myocytes [ 11,17,18] as 
well as other cell types, [19-22] probably reflecting a 
weak interaction of amylin at Gs-linked CGRP receptors in 
those cells. Indeed it has been suggested that the effects of 
amylin might be mediated via CGRP receptors, rather than 
via transduction through separate amylin receptors 
[17,19,21,23]. On the other hand, the effects of different 
agonists and antagonists argue for separate amylin and 
CGRP receptors [24,25]. The potency of amylin is greater 
than or equal to CGRP in its effects on soleus muscle 
glycogen metabolism [2,9,11,26] and its effects on plasma 
lactate and glucose in fasted anesthetized rats [16], but 
amylin is 100-fold less potent han CGRP as a vasodilator 
[27] and is 100- to 1000-fold less potent than CGRP in 
binding studies of CGRP receptors [ 17,18,20]. 
As yet there is no agreement on the signaling mecha- 
nisms by which amylin modulates keletal muscle glyco- 
gen metabolism. The observed biochemical effects of 
amylin, noted above, are similar to those evoked by agents 
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such as epinephrine that act via cAMP-mediated pathways. 
However, reports on the effects of amylin on cAMP levels 
in muscle have been contradictory. Some authors report no 
elevation of cAMP [11,12], whereas a preliminary report 
by Weiel et al. noted an increase [28], and 100 nM amylin 
was also reported to increase cAMP levels [29]. Further- 
more, in a recent report of effects of amylin in rat di- 
aphragms [30], amylin was shown to phosphorylate glyco- 
gen synthase at sites different from that observed by 
cAMP-dependent protein kinase (PKA) in vitro. The au- 
thors concluded that the effects of amylin on glycogen 
metabolism were therefore not accounted for solely by an 
increase in PKA. However, the phosphorylation of glyco- 
gen synthase by amylin that the authors observed was not 
different from that observed by others following 
epinephrine treatment in vivo [31,32]. This would suggest 
that, like epinephrine, amylin also activates Pka in skeletal 
muscle, as reported by Weiel et al. [28]. 
In an attempt o clarify the role of cAMP in amylin 
action on skeletal muscle, we re-examined the question of 
whether the metabolic effects of amylin in rat soleus 
muscle are associated with increases in cAMP formation, 
by conducting a series of time course and dose-response 
studies. Our results show that amylin potently increases 
cAMP levels, activates glycogen phosphorylase, depletes 
muscle glycogen stores and enhances production of lactate, 
with similar apparent ECs0's. 
2. Materials and methods 
2.1. Materials 
Rat amylin was obtained from Bachem California (Lot 
#B232 R01F, Torrence, Ca, USA), dissolved in deionized 
water in polypropylene tubes and stored at -70  ° C. Re- 
combinant human insulin (Humulin-R) was from Eli Lilly 
(Indianapolis, IN). Rp-8-CPT-cAMPS was from Biolog, 
Life Science Institute (La Jolla, CA). Stock solutions of 
amylin were tested for peptide and amino acid content 
[10]. Other chemicals were of reagent grade from Sigma 
(St. Louis, MO) or Fisher Scientific (Atlanta, GA). D-[U- 
14C]Glucose was from Amersham, and cAMP radioim- 
munoassay kit was from Biomedical Technologies 
(Stoughton, MA). Ecolite ® Scintillation fluid was from 
ICN Biomedicals (Irvine, CA). 
2.2. Soleus muscle dissection and incubation 
Soleus muscle strips were prepared from 4-h or 18-h 
fasted male Harlan Sprague-Dawley rats (150-200 g) by a 
modification of the method previously described in detail 
[10]. Muscle strips were pre-incubated for 20-30 min in 
physiological saline at room temperature and then in 
Krebs-Ringer bicarbonate (KRB) buffer containing 118.5 
mM NaCI, 5.94 mM KC1, 2.54 mM CaCI2, 1.19 mM 
MgSO 4, 1.19 mM KH2PO 4, 25 mM NaHCO 3 and 5.5 mM 
glucose (pH 7.3), and continuously gassed (95% 02:5% 
CO 2) during agitation at 37 ° C. Similar results were seen 
using soleus muscles from 4-h or 18-h fasted rats. Glyco- 
gen content and lactate production were higher and easier 
to measure in 4-h fasted rats; however, for cAMP and 
glycogen phosphorylase studies there was less variabilty 
and greater signal to noise in the results using 18-h fasted 
rats (results not shown). 
2.3. Glycogen mass determination 
Soleus muscle strips were incubated essentially as de- 
scribed in detail for determining the rates of [14C]glucose 
incorporation into soleus muscle glycogen [10]. Briefly, 
muscle pieces from 4-h fasted rats were incubated with rat 
amylin at the concentrations indicated, after which muscles 
were removed rapidly, blotted dry, trimmed of tendons, 
frozen in liquid N 2 and weighed. Glycogen was separated 
by ethanol precipitation of KOH digests of muscle [10]. 
Glycogen mass in precipitates was determined by measur- 
ing the glucose released from samples incubated with 
amyloglucosidase as described in detail previously [33]. 
Results are expressed as mg glycogen/g wet wt. of tissue. 
2.4. Lactate production 
Muscle pieces were incubated in saline (0.9% NaC1) for 
20 min to allow diffusion of intramuscular lactate, prior to 
being incubated as described above. A sample of the 
incubation medium was taken every 5 min throughout the 
experiment and assayed for lactate using a highly sensitive 
fluorometric method as previously described [34]. A rate of 
appearance of lactate in the medium was calculated for 
each incubation and expressed as /~mol lactate 
produced/min/g wet wt. of tissue, following corrections 
for diminution of volume due to sample withdrawal and 
for concentration of the incubation medium by evaporation 
as estimated by changes in Na+/K  + (Ciba-corning model 
614 Na+/K  + autoanalyzer). 
2.5. cAMP determination 
Muscle pieces from 18-h fasted rats were pre-incubated 
in 20 ml polyethylene scintillation vials with 2 ml of KRB 
buffer containing 0.1% fatty acid-free BSA for 30 rain in 
the presence or absence of insulin (7.1 nM) before use. Rat 
amylin or epinephrine was then added as indicated and 
incubations were generally continued for 10 min for 
dose-response curves, after which each muscle was 
weighed and frozen as described above. Phosphodiesterase 
inhibitor was not added in these incubations. 
For cAMP determinations, 0.5 ml of ice-cold trichloro- 
acetic (TCA) (5%) was added to each muscle piece and 
sonicated for 10 s at setting 10 on an MSE Soniprep 150 
fitted with an exponential microtip. Samples were neutral- 
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ized by the addition of 0.2 ml of 0.8 M Trizma, and spun 
briefly to separate particulate material, cAMP in the super- 
natant was determined by radioimmunoassay. Results are 
expressed as pmol cAMP/mg wet wt. of tissue. 
2.6. Glycogen phosphorylase a activity 
Glycogen phosphorylase a activity was determined in 
muscle pieces incubated as described for cAMP studies, 
from the rate of glucose 1-phosphate incorporation into 
glycogen as described previously [35,36], as measured by 
inorganic phosphate release [37]. Muscle pieces were soni- 
cated as described above in 1 ml of ice-cold buffer con- 
taining 100 mM NaF, 20 mM EDTA, 50 mM Trizma and 
0.5% glycogen (mussel) (pH 6.5). 0.2 ml of sample was 
added to 0.2 ml of incubation buffer containing 300 mM 
NaF, 50 mM glucose 1-phosphate, 10 mM caffeine and 
2% glycogen (pH 6.1) for determination f glycogen phos- 
phorylase a activity. Incubations for 20 min at 30°C were 
terminated by the addition of ice-cold 0.1 ml TCA (20%) 
and inorganic phosphate was measured using the ammo- 
nium molybdate method [37]. Results are expressed as 
pmol Pi produced/min/mg wet wt. of tissue. Total glyco- 
gen phosphorylase (a + b) activity, measured by the addi- 
tion of 1 mM 5'AMP and 500 mM NazSO 4 in the assay 
buffer [35], was not affected by amylin or epinephrine 
(results not shown). 
2.7. Numerical methods 
Amylin dose-response curves were performed on 2-4 
muscle strips per assay condition for each of the assays 
described above. The number of independent experiments 
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Fig. 1. Time course of the effects of amylin on cAMP accumulation. 
Muscles were preincubated for 130 min, then further incubated for the 
times indicated with or without 100 nM rat amylin, cAMP concentration 
was then determined as described. Results are means+ranges from 
n=2.  
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Fig. 2. Effects of amylin and insulin on cAMP levels in soleus muscle. 
Muscles were preincubated for 30 min in the presence or absence of 
insulin (7.1 nM) prior to the addition of rat amylin as indicated, for 10 
min cAMP levels in the muscle were then determined as described. 
Results are means 4-S.E. for n = 20 for each point from 9 independent 
experiments in the absence of insulin and n = 5 from 2 independent 
experiments in the presence of insulin. Estimated ECs0 for amylin = 0.48 
nM (+0.12 log units) and 0.3 nM (+0.18 log units) respectively. 
assay condition are specified in the relevant figure legend. 
Dose-response curves were fitted to a four-parameter lo-
gistic equation (Inplot; GraphPAD Software, San Diego, 
CA). ECs0 values, which are log-normally distributed are 
expressed as + S.E. of the logarithm [38]. Nominal con- 
centrations of amylin in the incubation buffer were as- 
signed by the standard practice of serial dilution of a 
weighed mass of peptide. The resulting concentrations 
were not confirmed by radioimmunoassay, as described 
elsewhere [10] to compensate for peptide loss on the 
surfaces of incubation vessels or in the tissue. The concen- 
trations and ECs0 values reported here therefore represent 
the upper bounds, i.e., it is probable that amylin concentra- 
tions at the surface of viable muscle fibers were lower than 
these nominal values and that amylin is more potent han 
the figures indicate. Paired analyses were performed using 
unpaired t-test (Instat; GraphPAD software, San Diego, 
CA). 
3. Results 
3.1. cAMP content 
Amylin elevated cAMP content in soleus muscles in the 
absence of added phosphodiesterase inhibitor. Fig. 1 shows 
an elevation in total cAMP content within 1 min of 
addition of 100 nM amylin to the incubation medium. 
cAMP reached a maximum within 5 min (1.24 + 0.01 
pmol/mg wet wt. from basal levels of 0.431 + 047 
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pmol /mg wet wt.), and returned to basal within 40 min. A 
similar time course and extent of rise in cAMP levels was 
seen with 1 /zM epinephrine (results not shown). 
Following a 10-min incubation in the absence of phos- 
phodiesterase inhibitor, amylin dose-dependently increased 
cAMP levels in soleus muscles with an apparent ECs0 of 
0.48 nM (+0.12 log units; Fig. 2). A 24 _+ 10% elevation 
of cAMP (P < 0.05, n = 20) was seen with a nominal 
concentration of amylin of 100 pM in these experiments 
(actual concentrations of amylin in the incubation buffer 
were not confirmed by radioimmunoassay). 
The magnitude of the increase in cAMP seen with 10 
nM amylin was similar to that seen with a maximally 
effective concentration of 1 /~M epinephrine (Fig. 5a). 
Preincubation of muscle pieces for 30 min with 7.1 nM 
insulin did not significantly affect amylin-mediated in- 
creases in cAMP (ECs0 of 0.3 nM+ 0.18 log units; n = 5, 
Fig. 4) which suggests that unlike in liver [39], cAMP- 
phosphodiesterase in muscle is not significantly regulated 
by insulin. 
3.2. Actiuation of glycogen phosphorylase 
Incubation of soleus muscle strips with amylin in- 
creased glycogen phosphorylase a, as previously reported 
[13]. The time course of activation of glycogen phospho- 
rylase (Fig. 3) with 100 nM amylin lagged the time course 
seen for cAMP elevation (Fig. 1). An increase in phospho- 
rylase a was detected within 2 min, and it reached a 
maximum at 20 min when fractional activity of phospho- 
rylase a was 14.1 _+ 2.5% of total compared with a basal 
activity of 3.2 + 0.3% (P  < 0.05). Phosphorylase a activ- 
ity returned to basal levels within 40 min. Similar results 
were seen with 1 tzM epinephrine (results not shown). 
It is difficult to determine if there is a parallel increase 
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Fig. 3. Time course of the effects of amylin on glycogen phosphorylase a 
activity. Muscles were incubated as in Fig. 1. Glycogen phosphorylase a 
activity was then determined as described. Results are means +ranges 
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Fig. 4. Effects of amylin and insulin on glycogen phosphorylase a activity 
in soleus muscle. Muscles were incubated as in Fig. 2, and glycogen 
phosphorylase a activity was measured as described. Results are means + 
S.E. for n = 21-23 for each point from 8 independent experiments in the 
absence of insulin and n = 9 from 3 independent experiments in the 
presence of insulin (7.1 nM). Estimated ECs0 for amylin in the absence 
of insulin = 2.2 nM (__.0.25 log units). 
in cAMP and glycogen phosphorylase a because of the 
variability of the data in Figs. 1 and 3. However, it can be 
seen that both cAMP levels and glycogen phosphorylase a 
activity are elevated within 2 min of addition of amylin 
and return to basal values within 40 min. 
The ECs0 for amylin-evoked increase in glycogen phos- 
phorylase a activity, following a 10-min stimulation, was 
2.2 nM (_  0.25 log units; Fig. 4). As seen with elevation 
of cAMP, the magnitude of increase of phosphorylase a 
following a 10-min incubation with 10 nM amylin was 
similar to that seen with 1 ~M epinephrine (Fig. 5b). 
Preincubation of muscle pieces for 30 min with 7.1 nM 
insulin markedly reduced the ability of subsequently added 
amylin to increase glycogen phosphorylase a measured at 
10 min (Fig. 4), consistent with previously reported inter- 
actions of insulin and amylin [13,30], or insulin and 
epinephrine [40], in skeletal muscle. 
3.3. IBMX potentiates and Rp-8-CPT-cAMPS inhibits 
amylin-euoked actiuation of glycogen phosphorylase a 
If the muscle effects of amylin are mediated mainly by 
cAMP-dependent mechanisms then IBMX, a cAMP-phos- 
phodiesterase inhibitor, should potentiate the effects of 
amylin, and Rp-8-CPT-cAMPS, a membrane permeant 
phosphodiesterase-resistant pro ein kinase A inhibitor, 
should inhibit the effects of amylin. 
Low IBMX concentrations (10 /zM) that did not mea- 
surably alter basal glycogen phosphorylase a activity, 
significantly enhanced the ability of 10 nM amylin to 
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Fig. 5. Comparison of the effects of amylin and epinephrine on (a) cAMP levels and (b) glycogen phosphorylase a activity in soleus muscle. Muscles 
pieces were incubated as described in Fig. 2. The mean values for cAMP and glycogen phosphorylase a activity in the presence of 10 nM rat amylin or 1 
p~M epinephrine are expressed as % of their respective control values. Results are expressed as means 5: S.E. For cAMP, n = 17 from 8 independent 
experiments for rat amylin and J~ = 6 from 2 independent experiments for epinephrine. For glycogen phosphorylase a, n = 21-23 from 8 independent 
experiments for rat amylin and n = 9-10 from 4 independent experiments for epinephrine. Basal values were 0.338 + 0.031 pmol/mg wet wt. and 
377 5:36 pmol/min/mg wet wt. for cAMP and glycogen phosphorylase a respectively. 
increase glycogen phosphorylase a from 88% to 287% 
over basal (P  < 0.05, Fig. 6a). 
Incubation with Rp-8 -CPT-cAMPS (500 FM)  did not 
affect basal g lycogen phosphorylase a activity, but re- 
duced the activation of  phosphorylase by 10 nM amylin 
from 94% over basal to 3:g% (P  < 0.001, Fig. 6b). Rp-8- 
CPT-cAMPS also reduced the ability of  100 nM 
epinephrine to stimulate glycogen phosphorylase a by 
44% under the same condit ions (results not shown; P < 
0.002). 
3.4. Effect of amylin on glycogen metabolism and lactate 
production 
As previously reported [9,10], amylin dose-dependent ly 
inhibits the rate of basal or insul in-st imulated radiolabelled 
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Fig. 6. Effects of (a) IBMX and (b) Rp-8-CPT-cAMPS on amylin-stimulated glycogen phosphorylase a activity in soleus muscle. Muscles were incubated 
as described in Fig. 4, except IBMX was added to some incubations 10 min prior and Rp-8-CPT-cAMPS 50 min prior to the addition of rat amylin. 
Glycogen phosphorylase a was then measured as described. Results are means + S.E. for n = 4 from 2 independent experiments for IBMX studies and 
means -1- S.E. for n = 11 from 3 independent experiments for Rp-8-CPT-cAMPS studies. 
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Fig. 7. Effects of amylin on (a) glycogen mass and (b) lactate production in soleus muscle. Muscles were preincubated for 30 min, then further incubated 
for 60 min in the presence of amylin as indicated. The rate of lactate production and the mass of glycogen remaining in the muscles following the 
incubation were determined as described. Results are means + S.E. from 4 independent experiments, each containing 4 muscle pieces. Estimated ECs0 for 
amylin = 0.9 nM (-1-0.22 log units) and 1.5 nM (+0.33 log units) for glycogen mass and lactate production respectively. 
glucose incorporation i to glycogen in isolated rat soleus 
muscle strips. In the absence of insulin, amylin dose-de- 
pendently decreased the glycogen content of soleus mus- 
cles by up to 75% with a calculated ECs0 of 0.9 nM 
(_  0.22 log units) as shown in Fig. 7a. 
Incubation with amylin also led to a dose-dependent 
two-fold increase in the rate of lactate production with a 
calculated ECs0 of 1.5 nM (_+ 0.33 log units) as shown in 
Fig. 7b. 
4. Discussion 
These data show that amylin potently increases cAMP 
levels in soleus muscle, with an ECs0 of 0.48 nM. Eleva- 
tion of cAMP was significant with as little as 100 pM 
amylin added and was observed in the absence of phospho- 
diesterase inhibitor. The concentrations and ECs0 reported 
here are very likely higher than the true values, because 
the concentrations were derived by weighing, dissolving 
and serially diluting the peptide. This method oes not take 
into account he peptide loss to incubation vessels and can 
markedly underestimate amylin potency [10]. For instance, 
in a previous tudy of rat, amylin effects on soleus muscle, 
nominal amylin concentrations of 1 nM, in fact gave 
values some 10-fold lower as assessed by radio-immunoas- 
say of the incubation medium. 
Our finding that amylin stimulates cAMP production is 
compatible with preliminary reports that amylin in the 
10-100 pM range activates cAMP-dependent protein ki- 
nase in soleus muscle [28], and dose-dependently activates 
adenylate cyclase in membrane fractions from rat skeletal 
muscle [41]. The magnitude and duration of the elevation 
of cAMP levels evoked by 10 nM maximally stimulating 
amylin was similar to that seen with 1 /xM maximally 
stimulating epinephrine (Fig. 5a). Our findings appear to 
be at variance with the conclusions of some authors who 
failed to see an increase in cAMP in amylin-treated soleus 
muscles [11,12], but they fit with the preliminary reports of 
others who observed increases in cAMP after amylin 
[28,29]. The state of the muscle prior to exposure to 
amylin may provide an explanation for the apparently 
discrepant reports. For example, basal levels of cAMP 
reported by [11] were approximately 10-fold higher than 
those reported here (Fig. 2) and elsewhere [28,29], suggest- 
ing that adenylyl cyclase may already have been activated. 
A predicted consequence of the elevation of cAMP in 
skeletal muscle is the phosphorylation f certain enzymes, 
such as glycogen phosphorylase and synthase, resulting in 
their respective activation and deactivation [30-32], lead- 
ing to the observed metabolic events. Our observation that 
IBMX, a cAMP phosphodiesterase inhibitor, potentiates 
(Fig. 6), and Rp-8-CPT-cAMPS, a membrane permeant 
phosphodiesterase-resistant protein kinase A inhibitor, de- 
creases (Fig. 6) the ability of amylin to increase glycogen 
phosphorylase a activity is consistent with amylin-elevat- 
ing cAMP levels in soleus muscle. The breakdown of 
glycogen, and inhibition of glycogen synthesis, will de- 
crease the labelling of glycogen, will deplete muscle 
glycogen stores, and if the resulting glycolytic flux ex- 
ceeds the oxidative capacity of the cell, there will be an 
increased production and effiux of lactate. The observation 
that these events all occur following amylin administration, 
and that their apparent ECs0 are near 1 nM in this system 
fits with causal inkage discussed above. 
Leighton and Cooper reported that isoprenaline and 
CGRP were equipotent at inhibiting glycogen accumula- 
tion in skeletal muscle, whereas isoprenaline was more 
potent han CGRP at stimulating lactate release [9]. These 
authors concluded that it was unlikely that CGRP, or 
R. Pittner et al . /  Biochimica et Biophysica Acta 1267 (1995) 75-82 81 
amylin, worked via the same signaling mechanism as 
fl-adrenergic agonists. However, our results, showing par- 
allel increases in the rates of lactate formation, cAMP 
accumulation and glycogen phosphorylase a and decreases 
in glycogen content following amylin treatment, are con- 
sistent with a single, cAMP, signaling pathway. It was also 
reported that CGRP, unlike insulin, does not stimulate 
lactate formation from extracellular glucose but rather 
from glycogenolysis [26]. The present data indicate that 
amylin, also, stimulates lactate production from glycogen. 
Over a 60-min incubation, 10 nM amylin decreased glyco- 
gen mass from 2.593 to 1.288 mg/g wet wt., which is 
equivalent to 134.1 nmol of glucose/min/g wet wt. Com- 
plete conversion to lactate would yield 268.2 nmol /min/g 
wet wt. 10 nM amylin increased the rate of lactate produc- 
tion from 0.156 to 0.269 ~mol /min /g  wet wt., which is 
equivalent o 113 nmol /min/g wet wt. It is therefore 
likely that the lactate released by amylin was mostly 
derived from endogenous glycogen. 
Amylin and epinephrine show similar actions on the 
disposition of muscle glycogen. Both decrease muscle 
glycogen, increase plasma lactate and subsequently in- 
crease liver glycogen [42-47]. While the results of amylin 
action are similar to those of epinephrine, they are medi- 
ated though distinct receptors in that they occur in the 
presence of fl-adrenergic blockade, [48]. Our results show 
that the magnitude of elevation of cAMP levels and of 
glycogen phosphorylase activity and duration of these 
events were similar for both amylin and epinephrine (Fig. 
5), consistent with amylin activating a cell surface receptor 
with high affinity for amylin and coupled to adenylyl 
cyclase. 
In conclusion, the data presented here support he con- 
cept that amylin acts on skeletal muscle via Gs-coupled 
receptors that (1) activate adenylate cyclase, (2) increase 
cAMP, (3) activate glycogen phosphorylase and (4) de- 
plete muscle glycogen stcres and enhance the production 
of lactate through glycoly,;is. 
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